Antidepressants: Clinically relevant drug interactions to be considered

Pharmacology

Volumn 86, Issue 4, 2010, Pages 203-215

  Schellander, Rene ^a   Donnerer, Josef ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Antidepressant drugs; Cytochrome P450; Drug interactions; Selective serotonin reuptake inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; AMPHETAMINE; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; CITALOPRAM; CYPROHEPTADINE; CYTOCHROME P450; DANTROLENE; DEXTROPROPOXYPHENE PLUS PARACETAMOL; DIAZEPAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENTANYL; FLUOXETINE; MOCLOBEMIDE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PROPOFOL; QUETIAPINE; ROFECOXIB; SEROTONIN 2A ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TETRACYCLIC ANTIDEPRESSANT AGENT; TRAMADOL; UNINDEXED DRUG; WARFARIN;

ALCOHOL ABUSE; ANTICHOLINERGIC EFFECT; ANTICOAGULATION; ANXIETY; BLEEDING; BRADYCARDIA; BRAIN HEMORRHAGE; CARDIOTOXICITY; CONSTIPATION; DEPRESSION; DIAPHORESIS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INTERACTION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TRANSFORMATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SUBSTRATE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERGLYCEMIA; HYPERREFLEXIA; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; LIMB TREMOR; LOW BACK PAIN; METABOLIC ACIDOSIS; METABOLIC DISORDER; MITRAL VALVE DISEASE; MITRAL VALVE REPLACEMENT; MUSCLE RIGIDITY; MYDRIASIS; MYOCLONUS; NEUROTRANSMISSION; PH; PLASMA PROTEIN BINDING; POLYPHARMACY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QT PROLONGATION; REVIEW; SEROTONIN SYNDROME; SMOKING; TACHYCARDIA; TENDON REFLEX;

ANIMALS; ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; HEMORRHAGE; HUMANS; LONG QT SYNDROME; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS;

EID: 77956386782     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319744     Document Type: Review

References (49)

1. Nemeroff CB, Preskorn SH, Devane CL: Antidepressant drug-drug interactions: clinical relevance and risk management. CNS Spectr 2007; 12(suppl 7):1-13.
2. Baxter K (ed): Stockley's Drug Interactions, ed 9. London, Pharmaceutical Press, 2010.
3. Schuler J, Dückelmann C, Beindl W, Prinz E, Michalski T, Pichler M: Polypharmacy and inappropriate prescribing in elderly internal- medicine patients in Austria. Wien Klin Wochenschr 2008; 120: 733-741.
4. Halkin H, Katzir I, Kurman I, Jan J, Malkin BB: Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 2001; 69: 260-265. (Pubitemid 32382509)
5. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 2004; 329: 15-19. (Pubitemid 38869995)
6. Alexopoulou A, Dourakis SP, Mantzoukis D, Pitsariotis T, Kandyli A, Deutsch M, Archimandritis AJ: Adverse drug reactions as a cause of hospital admissions: a 6-month experience in a single center in Greece. Eur J Intern Med 2008; 19: 505-510.
7. Brvar M, Fokter N, Bunc M, Mozina M: The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty. BMC Clin Pharmacol 2009; 9: 8.
8. Fokter N, Mozina M, Brvar M: Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments. Wien Klin Wochenschr 2010; 122: 81-88.
9. Ufer M, Meyer SA, Junge O, Selke G, Volz HP, Hedderich J, Gleiter CH: Patterns and prevalence of antidepressant drug use in the German state of Baden-Wuerttemberg: a prescription-based analysis. Pharmacoepidemiol Drug Saf 2007; 16: 1153-1160. (Pubitemid 350020070)
10. Interaction of tramadol with antidepressant drugs. GK Medinfo 2007, vol 17. http://www. stgkk.at/mediaDB/MMDB124658-MedInfo13-07.pdf.
11. Boyer EW, Shannon M: The serotonin syndrome. N Engl J Med 2005; 352: 1112-1120.
12. Shanmugam G, Kent B, Alsaiwadi T, Baskett R: Serotonin syndrome following cardiac surgery. Interact Cardiovasc Thorac Surg 2008; 7: 656-657.
13. Sener S, Yamanel L, Comert B: A fatal case of severe serotonin syndrome accompanied by moclobemide and paroxetine overdose. Indian J Crit Care Med 2005; 9: 173-175. (Pubitemid 43185122)
14. Mahlberg R, Kunz D, Sasse J, Kirchheiner J: Serotonin syndrome with tramadol and citalopram. Am J Psychiatry 2004; 161: 1129.
15. Kitson R, Carr B: Tramadol and severe serotonin syndrome. Anaesthesia 2005; 60: 934-935.
16. Frank C: Recognition and treatment of serotonin syndrome. Can Fam Physician 2008; 54: 988-992.
17. Interaction of triptans with SSRI and SNRI. GK Medinfo 2006, vol 16. http://www.stgkk. at/mediaDB/MMDB115343-MedInfo6-06-0.pdf.
18. Evans RW: The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and triptans: an analysis of the 29 case reports. Med Gen Med 2007; 9: 48.
19. Sclar DA, Robison LM, Skaer TL: Concomitant triptan and SSRI or SNRI use: a risk for serotonin syndrome. Headache 2008; 48: 126-129.
20. Kharofa J, Sekar P, Haverbusch M, Moomaw C, Flaherty M, Kissela B, Broderick J, Woo D: Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke 2007; 38: 3049-3051. (Pubitemid 350035702)
21. Schalekamp T, Klungel OH, Souverein PC, de Boer A: Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008; 162: 180-185. (Pubitemid 351185885)
22. Tata LJ, Fortun PJ, Hubbard RB, Smeeth L, Hawkey CJ, Smith CJ, Whitaker HJ, Farrington CP, Card TR, West J: Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal antiinflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 2005; 22: 175-181. (Pubitemid 41153059)
23. Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J: Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009; 104: 1475-1482.
24. Wallerstedt SM, Gleerup H, Sundström A, Stigendal L, Ny L: Risk of clinically relevant bleeding in warfarin-treated patients - Influence of SSRI treatment. Pharmacoepidemiol Drug Saf 2009; 18: 412-416.
25. de Jong JC, van den Berg PB, Tobi H, de Jongvan den Berg LT: Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol 2003; 55: 591-595. (Pubitemid 36783201)
26. Sala M, Coppa F, Cappucciati C, Brambilla P, d'Allio G, Caverzasi E, Barale F, De Ferrari GM: Antidepressants: their effects on cardiac channels, QT prolongation and torsade de pointes. Curr Opin Investig Drugs 2006; 7: 256-263.
27. Sumic JC, Baric V, Bilic P, Herceg M, Sisek- Sprem M, Jukic V: QTc and psychopharmacs: are there any differences between monotherapy and polytherapy. Ann Gen Psychiatry 2007; 6: 13. (Pubitemid 46813766)
28. Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, Bonzano A, Piccinelli M, Barale F, De Ferrari GM: QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry 2005; 4: 1. (Pubitemid 40854389)
29. Vieweg WV, Wood MA: Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics 2004; 45: 371-377. (Pubitemid 39166908)
30. Van Noord C, Straus SM, Sturkenboom MC, Hofman A, Aarnoudse AJ, Bagnardi V, Kors JA, Newton-Cheh C, Witteman JC, Stricker BH: Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol 2009; 29: 9-15.
31. Letsas K, Korantzopoulos P, Pappas L, Evangelou D, Efremidis M, Kardaras F: QT interval prolongation associated with venlafaxine administration. Int J Cardiol 2006; 109: 116-117. (Pubitemid 44415035)
32. Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG: QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother 2005; 39: 543-546.
33. De Gregorio C, Morabito G, Cerrito M, Dattilo G, Oreto G: Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapies and illnesses. Int J Cardiol 2009, E-pub ahead of print.
34. De Boer RA, van Dijk TH, Holman ND, van Melle JP: QT interval prolongation after sertraline overdose: a case report. BMC Emerg Med 2005; 5: 5.
35. Service JA, Waring WS: QT prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin Toxicol (Phila) 2008; 46: 71-73.
36. Eckert A: Clinically relevant drug interactions with new generation antidepressants and antipsychotics (in German). Ther Umsch 2009; 66: 485-492.
37. Spina E, Santoro V, D'Arrigo C: Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008; 30: 1206-1227.
38. Billups SJ, Delate T, Dugan D: Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations. Pharmacoepidemiol Drug Saf 2009; 18: 253-257.
39. Jefferson JW: Drug interactions - friend or foe? J Clin Psychiatry 1998; 59(suppl 4):37-47.
40. Onalan O, Cumurcu BE, Bekar L: Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine. Mayo Clin Proc 2008; 83: 595-599. (Pubitemid 351717009)
41. Ereshefsky L: Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996; 16(suppl 2):37S-50S. (Pubitemid 126730222)
42. Ereshefsky L, Jhee S, Grothe D: Antidepressant drug-drug interaction profile update. Drugs R D 2005; 6: 323-336. (Pubitemid 41633387)
43. Shin JG, Park JY, Kim MJ, Shon JH, Yoon YR, Cha IJ, Lee SS, Oh SW, Kim SW, Flockhart DA: Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos 2002; 30: 1102-1107.
44. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007; 151: 737-748.
45. Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H: The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol 2006; 62: 512-526. (Pubitemid 44571572)
46. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V: Hyperforin in St John's wort drug interactions. Eur J Clin Pharmacol 2006; 62: 225-233. (Pubitemid 43357581)
47. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P: St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54: 349-456. (Pubitemid 35334946)
48. Lemmer B, Brune K: Pharmakotherapie: Klinische Pharmakologie, ed 13. Heidelberg, Springer, 2007.
49. Mallet L, Spinewine A, Huang A: The challenge of managing drug interactions in elderly people. Lancet 2007; 370: 185-191. (Pubitemid 47042897)